Putnam Global Health Care A holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
Putnam Global Health Care Fund Class A PHSTX
- NAV / 1-Day Return 62.25 / −0.94 %
- Total Assets 1.5B
-
Adj. Expense Ratio
1.040%
- Expense Ratio 1.040%
- Distribution Fee Level Low
- Share Class Type Front Load
- Category Health
- Investment Style Large Value
- Min. Initial Investment 0
- Status Open
- TTM Yield 0.23%
- Turnover 67%
USD | NAV as of Jun 18, 2026 | 1-Day Return as of Jun 18, 2026, 12:11 AM GMT+0
Morningstar’s Analysis PHSTX
Will PHSTX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
The People Pillar is our evaluation of the PHSTX management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of PHSTX’s parent organization’s priorities and whether they’re in line with investors’ interests.
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 61.1
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 13.16 | 193M | Healthcare |
Johnson & Johnson | 8.47 | 124M | Healthcare |
UnitedHealth Group Inc | 6.94 | 102M | Healthcare |
AbbVie Inc | 6.05 | 89M | Healthcare |
Novartis AG Registered Shares | 5.14 | 75M | Healthcare |
Buy Euro - Sell U S Dollar | 5.07 | 74M | Derivative |
Merck & Co Inc | 4.88 | 71M | Healthcare |
Buy U S Dollar - Sell Euro | 4.81 | 70M | Derivative |
AstraZeneca PLC | 4.68 | 68M | Healthcare |
Thermo Fisher Scientific Inc | 4.51 | 66M | Healthcare |
United States